PS-002 for the Treatment of IgA Nephropathy in Adults

Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2025
The purpose of the study is to evaluate safety, tolerability, and preliminary effectiveness following administration of PS-002 in adults with primary Immunoglobulin A (IgA) nephropathy. This will be a first-in-human study and will include participants at high risk of disease progression despite receiving current standard-of-care treatment. Participants will be monitored for up to one year after receiving PS-002 and invited to take part in a long-term follow-up study (total follow-up: 5 years).
Epistemonikos ID: 0451c6fbc4d02cdaddd3dcd80dcf31ae6ecea050
First added on: Sep 20, 2025